Recently Prescribed Cannabis Did Not Mean Cannabis-Naive in the Cognitive Studies

Some participants had only recently started medicinal cannabis but reported many years of non-prescribed use. Time since prescription was therefore a different exposure-history measure from time since first cannabis use.

The study recorded both histories

The oral and flower groups reported months of medicinal treatment and longer histories of cannabis use. Among participants with three months or less of medicinal use, several had at least five years of prior non-prescribed use. In the flower sample, the paper identified eleven such participants.

A treatment label does not define adaptation

Someone newly receiving a prescription may already have extensive experience with THC. Conversely, prescription status alone cannot establish tolerance to every acute effect. Combining these people into a generic new-user category would conceal the history relevant to interpretation.

The distinction limits comparisons with first exposure

The cognitive results came largely from frequent users with heterogeneous treatment and use histories. They should not be transferred automatically to a person taking THC for the first time. The self-reported histories also do not prove the extent of any individual’s physiological adaptation. For an evidence review, distinguish onset of cannabis use, recent frequency, formulation experience and onset of prescribed treatment. Each can inform a different question, and no single administrative date substitutes for the complete history.

Related analysis: the study’s main findings and limitations.

Research cited

Stefanidis and colleagues. Elucidating the acute effects of medically prescribed oral and vaporised delta-9-tetrahydrocannabinol on cognitive functions important for driving. Drug and Alcohol Review (2025). DOI: 10.1111/dar.14060.

Spread the love


The National Black Lawyers

top 40 lawyers

civil trial law

Lawyers of Distinction

Loading...

Recent Blog Articles

CBD Memory Findings in Cerebral-Malaria Mice Involved Adjunctive Antimalarial Treatment

A mouse cerebral-malaria experiment summarized in the CBD brain review reported memory findings when CBD was added to artesunate. The observation concerned adjunctive treatment in an infectious-disease model, rather than CBD alone as a general memory enhancer. The disease and co-treatment belonged in the result The review describes CBD treatment…

Spread the love

Read Article: CBD Memory Findings in Cerebral-Malaria Mice Involved Adjunctive Antimalarial Treatment

Serotonin Blockade Qualified CBD Pain Mechanisms Differently Across Rat Models

Rat experiments summarized in the CBD brain review found different degrees of interference with CBD-related pain responses after serotonin-receptor blockade. The evidence did not establish one exclusive mechanism for every model. The diabetic and nerve-injury models differed In male diabetic rats, the review reports attenuation of mechanical allodynia with CBD…

Spread the love

Read Article: Serotonin Blockade Qualified CBD Pain Mechanisms Differently Across Rat Models

Attrition and Incomplete Dosing Complicated an Observational CBD Pain Report

An observational CBD study summarized in the brain-function review reported improvement in pain patients but had substantial participant loss and incomplete dosing information. Those limitations constrained attribution of the change to CBD. The clinical groups did not report one uniform response The review describes Gulbransen and colleagues’ exploratory quality-of-life study….

Spread the love

Read Article: Attrition and Incomplete Dosing Complicated an Observational CBD Pain Report

Speak with an expert today!

Contact the offices of Okorie Okorocha for professional and reliable advice which you can trust.

Call (424) 363-3347 Contact Us